AFTIN

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/667.167 **TRANSMITTAL** Filing Date 09/17/2003 First Named Inventor **FORM** Michael J. Munchhof, et al. Art Unit Examiner Name P. Morris (to be used for all correspondence after initial filing) Attorney Docket Number PC25396A Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC < Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a **Provisional Application** Proprietary Information After Final Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please Identify **Terminal Disclaimer Extension of Time Request** below): Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Pfizer Inc Signature Printed name Nicholas J. Sisti Date Reg. No. 54,453 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date Janice Denison

equired by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Typed or printed name

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed MS Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 12th day of May, 2005. Janice Denison (Typed or printed name of person) IN THE UNITED STATES PATENT AND TRADEMARK OFFICE IN RE APPLICATION OF: Munchhof, Michael, J., et al. Examiner: P. Morris **APPLICATION NO.: 10/667,167** Group Art Unit: 1625 FILING DATE: September 17, 2003 Confirmation No. 8566 TITLE: Novel Isothiazole and Isooxazole Compounds as Transforming Growth Factor

(TGF) Inhibitors

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Amendment and Response Under 37 CFR § 1.116

In response to the Office Action dated May 6, 2005, Applicants respectfully request reconsideration of the subject application in view of the following remarks. This response is filed within the shortened statutory period of three months and within two months of the mailing date of this Final Action.

Amendments to the claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks / Arguments begin on page 5 of this paper.